Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents
L Zhong, W Zhang, C Krummenacher, Y Chen… - Trends in …, 2023 - cell.com
Herpesviruses are among the most successful viruses found in human populations. They
establish lifelong latent infections, which are punctuated by recurrent reactivations. The entry …
establish lifelong latent infections, which are punctuated by recurrent reactivations. The entry …
Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy
C Xie, LY Zhong, GL Bu, GX Zhao… - Journal of Medical …, 2023 - Wiley Online Library
Epstein‐Barr virus (EBV) infection is prevalent in global population and associated with
multiple malignancies and autoimmune diseases. During the infection, EBV‐harbored or …
multiple malignancies and autoimmune diseases. During the infection, EBV‐harbored or …
A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice
CJ Wei, W Bu, LA Nguyen, JD Batchelor… - Science translational …, 2022 - science.org
Epstein-Barr virus (EBV) is the major cause of infectious mononucleosis and is associated
with several human cancers and, more recently, multiple sclerosis. Despite its prevalence …
with several human cancers and, more recently, multiple sclerosis. Despite its prevalence …
A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV
Epstein-Barr virus (EBV) is a global public health concern, as it is known to cause multiple
diseases while also being etiologically associated with a wide range of epithelial and …
diseases while also being etiologically associated with a wide range of epithelial and …
Immunization with a self-assembling nanoparticle vaccine displaying EBV gH/gL protects humanized mice against lethal viral challenge
Epstein-Barr virus (EBV) is a cancer-associated pathogen responsible for 165,000 deaths
annually. EBV is also the etiological agent of infectious mononucleosis and is linked to …
annually. EBV is also the etiological agent of infectious mononucleosis and is linked to …
Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells
Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with B cell
lymphomas. EBV glycoprotein 42 (gp42) binds HLA class II and activates membrane fusion …
lymphomas. EBV glycoprotein 42 (gp42) binds HLA class II and activates membrane fusion …
Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS
J Joseph, G Sandel, R Kulkarni, R Alatrash, BB Herrera… - Pathogens, 2023 - mdpi.com
Infectious agents, notably viruses, can cause or increase the risk of cancer occurrences.
These agents often disrupt normal cellular functions, promote uncontrolled proliferation and …
These agents often disrupt normal cellular functions, promote uncontrolled proliferation and …
Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infection
Epstein-Barr virus (EBV) is closely associated with cancer, multiple sclerosis, and post-acute
coronavirus disease 2019 (COVID-19) sequelae. There are currently no approved …
coronavirus disease 2019 (COVID-19) sequelae. There are currently no approved …
Well Put Together—A Guide to Accessorizing with the Herpesvirus gH/gL Complexes
GL Gonzalez-Del Pino, EE Heldwein - Viruses, 2022 - mdpi.com
Herpesviruses are enveloped, double-stranded DNA viruses that infect a variety of hosts
across the animal kingdom. Nine of these establish lifelong infections in humans, for which …
across the animal kingdom. Nine of these establish lifelong infections in humans, for which …
A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus
Abstract Background Epstein-Barr virus (EBV) is a wide-spread human herpesvirus that is
highly associated with infectious mononucleosis and several malignancies. Evaluation of …
highly associated with infectious mononucleosis and several malignancies. Evaluation of …